ACHP’s responds to Medicare’s proposal to sharply limit coverage of the controversial Alzheimer’s drug Aduhelm.
Drug Pricing
Securing Affordable Treatments for All Americans
Left unchecked, the pharmaceutical industry continues to set exorbitant drug prices and hinder competition in the marketplace. ACHP advocates for policies that promote reasonable prescription drug prices and ensure a sustainable health care system that works for patients and health plans alike. ACHP is dedicated to cracking down on anticompetitive practices, spurring development of generic and biosimilar treatments and increasing transparency around price setting.
To the Point
-
12/22/2021
BLOG — Aduhelm’s Price Cut Misses the Mark
Besides being outrageously priced, Aduhelm is an unproven, potentially dangerous drug—a drug Medicare simply should not cover. -
08/25/2021
POLICY POSITIONING — Curbing High Drug Costs
ACHP's bipartisan policy recommendations will help hold drug makers accountable and curb exorbitantly high drug costs. -
03/06/2020
FACT SHEET — Support Legislation to Reduce Drug Prices
Legislation can help check drug makers ability to hike prices and inject more competition into the market — helping lower prices for all. -
04/08/2019
INFOGRAPHIC — A Unique Approach: Transparent PBMs
ACHP member health plans run fully transparent, fee-based PBMs that keep drug costs in check. -
10/05/2018
INFOGRAPHIC — Biosimilars: An Antidote For High Prices
Millions struggle to pay high drug prices, forcing them to choose either medication or other expenses. Our infographic explains how “biosimilars” can help.
Deep Dive
-
12/23/2021
PODCAST—Build Back Better, ACA and Drug Pricing on Kaiser Health News’ What the Health?
ACHP's Ceci Connolly discusses the Build Back Better Act, ACA enrollment, drug pricing and more on KHN's What the Health? podcast. -
10/21/2021
LETTER — ACHP Urges Lawmakers to Include Vital Health Provisions in Build Back Better Act
ACHP urges lawmakers debating the Build Back Better Act to include important health provisions that will expand access and lower costs. -
09/01/2021
VIDEO — Tackling High-Cost Specialty Drugs and Preserving Patient Centered Innovation (Webinar)
ACHP examines how organizations are managing high-cost specialty drugs to ensure patients get the drugs they need without breaking the bank. -
08/27/2021
ISSUE BRIEF — Lowering Drug Costs through Transparency and Competition
ACHP proposes bold reforms aimed at lowering drug costs by promoting transparency, competition and innovation. -
06/17/2021
OP-ED — Community Health Plans Are Serious: Support Major Federal Action to Reduce Prescription Drug Costs
ACHP backs concrete efforts by the federal government to reign in high drug costs, such as empowering Medicare negotiations.
Resource Library Search
CLIP — The Wall Street Journal: ACHP Responds to New Rapid At-Home COVID Test White House Policy
Following a White House announcement, ACHP responds to the lack of a coordinated national testing strategy and rapid at-home COVID test availability.
BLOG — Aduhelm’s Price Cut Misses the Mark
Besides being outrageously priced, Aduhelm is an unproven, potentially dangerous drug—a drug Medicare simply should not cover.
CLIP — The New York Times: ACHP Responds to Rushed Testing Implementation Timeline
ACHP spoke with Sarah Kliff about the rushed testing implementation timeline following new rules requiring at-home COVID test coverage.
FACT SHEET — Medicare Advantage: Choosing Coverage and Care that Meets Your Needs
When choosing a Medicare Advantage (MA) plan, there are several factors to consider. Fortunately, a lot of information – including network, pricing, performance in treating certain conditions and quality ratings – is publicly available.
FACT SHEET — Medicare Advantage: Serving a Diverse, Rapidly Growing Population
Medicare Advantage (MA) serves diverse populations. In fact, MA enrolls a higher percentage of people of color than traditional Medicare.